Investigating the Cell Origin and Liver Metastasis Factors of Colorectal Cancer by Single-Cell Transcriptome Analysis

DOI: https://doi.org/10.2147/ott.s454295

IF: 4

2024-04-18

OncoTargets and Therapy

Abstract:Zhilin Sha, 1, &ast Qingxiang Gao, 1, &ast Lei Wang, 2, &ast Ni An, 3 Yingjun Wu, 1 Dong Wei, 4 Tong Wang, 5 Chen Liu, 1 Yang Shen 1 1 Department I of Biliary Tract Surgery, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, People's Republic of China; 2 Department of General Surgery, Yancheng Hospital of Traditional Chinese Medicine, Yancheng, Jiang Su, People's Republic of China; 3 Department of Anesthesiology, the Eighth Medical Center of Chinese PLA General Hospital, Beijing, People's Republic of China; 4 Department of General Surgery (Second Ward), the No.1 People's Hospital of Pinghu, Pinghu, Zhe Jiang, People's Republic of China; 5 Department of Anesthesiology, No.32295 Troop of Chinese PLA, Liaoyang, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yang Shen, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, No. 700 of North Moyu Road, Jia Ding District, Shanghai, 201823, People's Republic of China, Email Chen Liu, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, No. 700 of North Moyu Road, Jia Ding District, Shanghai, 201823, People's Republic of China, Email Background: Colorectal cancer (CRC) is one of the deadliest causes of death by cancer worldwide. Liver metastasis (LM) is the main cause of death in patients with CRC. Therefore, identification of patients with the greatest risk of liver metastasis is critical for early treatment and reduces the mortality of patients with colorectal cancer liver metastases. Methods: Initially, we characterized cell composition through single-cell transcriptome analysis. Subsequently, we employed copy number variation (CNV) and pseudotime analysis to delineate the cellular origins of LM and identify LM-related epithelial cells (LMECs). The LM-index was constructed using machine learning algorithms to forecast the relative abundance of LMECs, reflecting the risk of LM. Furthermore, we analyzed drug sensitivity and drug targeted gene expression in LMECs and patients with a high risk of LM. Finally, functional experiments were conducted to determine the biological roles of metastasis-related gene in vitro. Results: Single-cell RNA sequencing analysis revealed different immune landscapes between primary CRC and LM tumor. LM originated from chromosomal variants with copy number loss of chr1 and chr6p and copy number gain of chr7 and chr20q. We identified the LMECs cluster and found LM-associated pathways such as Wnt/beta-catenin signaling and KRAS signaling. Subsequently, we identified ten metastasis-associated genes, including SOX4, and established the LM-index, which correlates with poorer prognosis, higher stage, and advanced age. Furthermore, we screened two drugs as potential candidates for treating LM, including Linsitinib_1510, Lapatinib_1558. Immunohistochemistry results demonstrated significantly elevated SOX4 expression in tumor samples compared to normal samples. Finally, in vitro experiments verified that silencing SOX4 significantly inhibited tumor cell migration and invasion. Conclusion: This study reveals the possible cellular origin and driving factors of LM in CRC at the single cell level, and provides a reference for early detection of CRC patients with a high risk of LM. Keywords: colorectal cancer, liver metastasis, single-cell sequencing, SOX4, prognostic Colorectal cancer (CRC) is one of the most common malignant tumors in the digestive tract, with the second highest incidence and mortality rate of cancer. 1,2 Early clinical symptoms are not obvious, but symptoms such as blood in stool, constipation and abdominal pain appear with increasing tumor extent, which seriously affects the quality of life of patients. 3,4 Since CRC is highly heterogeneous, clinical indicators and prognosis are quite different, especially in the stage II and III stages of CRC. 5 Currently, the preferred treatments are radiotherapy and surgical resection of the lesion site. 6 However, the rapid disease progression of CRC, with the majority of patients presenting with liver metastasis, makes it particularly important to assess risk stratification and identify patients with early metastases. 7 The liver is the main target organ of CRC metastasis. About a quarter of patients with CRC have the symptom of liver metastasis at the time of diagnosis, and more patients get liver metastasis after surgical eradication of the primary tumor. 8 Nearly 90% of patients cannot be completely eradicated after the occurrence of liver metastasis, which -Abstract Truncated-

oncology,biotechnology & applied microbiology